System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maura Massimino is an expert in Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori (Italy). As of October 2026, ScienceLeadR ranks Maura Massimino in the top 1% of experts worldwide for Brain Neoplasms, Glioma and Nervous System Neoplasms. Maura Massimino has authored 600 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 3 of them ongoing. SLR score: 1,863 (community average: 125). How the SLR is computed.

LeadR Profile

Maura Massimino Fondazione IRCCS Istituto Nazionale dei Tumori Italy
1 863 ScienceLeadR Reputation 1863

Unlock

Register Login
Network Map

Oncology

Subspecialties: Neurology - Pediatrics - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1992 - 2026
Source: PubMed

Fondazione IRCCS Istituto Nazionale dei Tumori

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 600

Citations

Citations: 14 651 1st author: 72 Last author: 131 Unique author: 1

Main journals

Neuro Oncol 96
Pediatr Blood Cancer 65
Tumori 56
J Neurooncol 26
J Clin Oncol 24

Best Journals

J Clin Oncol 5
Lancet Oncol 5
Nature 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
A pediatric high-grade B-cell lymphoma with a rare complex cytogenetic profile: A case report.
PMID 42927442 — cells, lymphoma, b-cell, lymphoma, neoplasms, therapeutics, cytogenetics, b-lymphocytes		Tumori20260
Spirituality in Multicultural Pediatric Oncology End-of-Life Care: Four Cases.
PMID 42861447 — terminal care, work, pediatrics, spirituality		Clin Pediatr (Phila)20260
Overcoming emerging challenges in childhood cancer survivorship: a spotlight on pediatric CNS tumors.
PMID 42726273 — proton therapy, fertility preservation, neoplasms, survivorship, therapeutics		Expert Rev Anticancer Ther20260
Hypertension in Wilms Tumor at Diagnosis: Proposed Treatment Recommendations Starting From a Bi-Institutional Retrospective Observational Study.
PMID 42610384 — hypertension, neoplasms, antihypertensive agents, wilms tumor, diagnosis, therapeutics		Pediatr Blood Cancer20260
The VIVA Regimen (Vinorelbine, Ifosfamide, Vincristine, and Actinomycin-D) for High-Risk Rhabdomyosarcoma: Feasibility and Outcomes From a Single-Institution Study.
PMID 42527384 — rhabdomyosarcoma, ifosfamide, neoplasms, drug therapy, vinorelbine, vincristine, dactinomycin, therapeutics, chemotherapy		Pediatr Blood Cancer20260

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Chair: 1

By phase:

Phase 2 6
Phase 3 3
N/A 1
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 5
Recruiting 5
Active not recruiting 2

By type:

Interventional 11
Observational 1

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 2
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Randomized study to protect from radiation iatrogenic hypothyroidism patients with medulloblastoma (any stage any biological risk) and pediatric patients with Hodgkin lymphoma and non Hodgkin lymphoma needing radiation therapy on thyroid site WINHYPO 2021
2024-512642-42-00 — radiotherapy, hodgkin disease, lymphoma, thyroid gland, medulloblastoma, hypothyroidism, lymphoma, non-hodgkin, therapeutics		Phase 3Recruiting2021
European Prospective Investigation Into Childhood Cancer
NCT05375617 — brain neoplasms, cells, precursor cell lymphoblastic leukemia-lymphoma, life style, lymphoma, brain, neoplasms, leukemia, nutritional status, child		N/ARecruiting2023
TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients
NCT05316922 — radiotherapy, pharmaceutical preparations, thyroxine, neoplasms, thyroid gland, hormones, hypothyroidism, therapeutics		Phase 3Recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS